Autonomix Medical (AMIX) Q3 2025 earnings summary

Executive summary

• Focused on developing catheter-based technology for sensing and treating nervous system disorders, with initial application in pancreatic cancer pain management.

• No revenues reported; company remains in clinical-stage development.

• Completed a 1-for-20 reverse stock split in October 2024 to regain Nasdaq compliance.

• Closed a public offering in November 2024, raising $10.0 million gross ($9.0 million net cash proceeds).

Financial highlights

• Net loss of $2.7 million for the quarter ended December 31, 2024, compared to $3.1 million for the same quarter last year.

• Net loss of $8.2 million for the nine months ended December 31, 2024, versus $10.0 million for the same period in 2023.

• Cash and cash equivalents were $11.8 million as of December 31, 2024, up from $8.6 million at March 31, 2024.

• Working capital stood at $9.7 million at December 31, 2024.

• No revenue recognized for the three and nine months ended December 31, 2024 and 2023.

Outlook and guidance

• Current cash resources are expected to fund operations into, but not beyond, the first calendar quarter of 2026.

• Additional financing of $30–$35 million estimated to be required to reach commercialization of the first product.

• No expectation of positive cash flows from operations in the near future.